Clinical Research Details
Title:
S0801 A Phase II Study of Iodine-131 Labeled Tositumomab in Combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy For Patients With Advanced Stage Follicular Non-Hodgkin's Lymphoma
Purpose:
To evaluate response rate and toxicity in participants with advanced stage follicular NHL treated with R-CHOP + I-131 tositumomab with rituximab maintenance; to estimate the three-year and five-year progression-free survival rate; to assess the safety profile of rituximab maintenance following the R-CHOP + I-131 tositumomab regimen.
Study Number:
201434012109
Number of Patients:
80
Elgibility:
Previously untreated Stage III, IV, or bulky stage II follicular B-cell NHL; + CD 20. Cardiac EF >45%
Treatment:
You will receive treatment every 21 days for six cycles followed by restaging and treatment with tositumomab. Maintenance therapy will then be added for up to four years.
Principal Investigator:
Enrollment Phone:
(708) 327-3223